Stada Arzneimittel (OTCMKTS:STDAF) Given Sell Rating at DZ Bank

DZ Bank reaffirmed their sell rating on shares of Stada Arzneimittel (OTCMKTS:STDAF) in a report released on Wednesday, December 20th.

Shares of Stada Arzneimittel (OTCMKTS STDAF) remained flat at $$100.50 on Wednesday. The stock has a market cap of $6,270.00, a price-to-earnings ratio of 61.28 and a beta of 1.41. Stada Arzneimittel has a 12 month low of $51.40 and a 12 month high of $100.50.

WARNING: This report was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at

About Stada Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply